MMR vaccine (measles, mumps, rubella)
واکسن سرخک، اوریون و سرخجه (MMR)
🦠 Antiinfectives For Systemic UseLive attenuated vaccine
Market / country: 🇺🇸 USA
M-M-R II (US)
🧮 Dose calculator
Immunisation (vaccination) · Regimen source: FDA M-M-R II · 2.1
- • The second dose may be given before 4 y if at least 1 month apart. Measles post-exposure: one dose within 72 h. IM or SC. FDA M-M-R II · 2.1
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Pregnancy, immunosuppression, moderate or severe febrile illness, active untreated tuberculosis (live vaccine). FDA M-M-R II · 4
- ⛔ Severe allergic reaction to a vaccine component (including gelatin and neomycin) or a previous dose. FDA M-M-R II · 4
Formulations
- 0.5 mL dose after reconstitution — injection 🇺🇸 USA FDA M-M-R II · 3
👥 Special populations
- 🤰 PregnancyContraindicated
Label: contraindicated in pregnancy. FDA M-M-R II · 4
“( 4.4 ) Pregnancy.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA M-M-R II · 8.2
“Studies have shown that lactating postpartum women vaccinated with live attenuated rubella vaccine may secrete the virus in breast milk and transmit it to breast-fed infants. { 17 , 18 } In the breast-fed infants with serological evidence of rubella virus vaccine strain antibodies, none exhibited severe disease; …”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA M-M-R II · 8.4
“Safety and effectiveness of measles vaccine in infants below the age of 6 months have not been established [see Clinical Studies (14) ] .”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA M-M-R II · 8.5
“Clinical studies of M-M-R II did not include sufficient numbers of seronegative subjects aged 65 and over to determine whether they respond differently from younger subjects.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)BLA101069
- DailyMed (FDA label)FDA M-M-R II
- MedlinePlus (NIH)❌ None
- WHO ATC/DDDJ07BD52
- Darooyab (Iran)Measles,-Mumps,-and-Rubella-Vaccines
🇮🇷 Registered in Iran Darooyab · G-3486/Measles,-Mumps,-and-Rubella-Vaccines
Dosage forms with Iranian generic codes, per Darooyab.
- 01578 · VACCINE-MEASLES+MUMPS+RUBELLA VIRUS 10DOSE VIAL · ویال واکسن–سرخک + اوریون + سرخجه ویروس ۱۰ دوز
- 07629 · VACCINE-MEASLES+MUMPS+RUBELLA VIRUS 1DOSE VIAL · ویال واکسن–سرخک + اوریون + سرخجه ویروس ۱ دوز
- 09575 · VACCINE-MEASLES+MUMPS+RUBELLA VIRUS 2DOSE VIAL · ویال واکسن–سرخک + اوریون + سرخجه ویروس ۲ دوز
- 01990 · VACCINE-MEASLES+RUBELLA (10 dose) VIAL · ویال واکسن–سرخک + سرخجه (۱۰ دوز)
- 50415 · MEASLES / MUMPS / RUBELLA VACCINE INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION PARENTERAL 5 {dose} 2.5 mL · محلول تزریقی واکسن سرخک / اوریون / سرخجه ۵ { دوز } ۲٫۵ میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA M-M-R II · 3FDA M-M-R II · 2.1FDA M-M-R II · 4FDA M-M-R II · 8.2FDA M-M-R II · 8.4FDA M-M-R II · 8.5FDA M-M-R II · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-3486/Measles,-Mumps,-and-Rubella-Vaccines
- Clinical review⚠ Unverified